Literature DB >> 27148232

Comparison between Immunization Routes of Live Attenuated Salmonella Typhimurium Strains Expressing BCSP31, Omp3b, and SOD of Brucella abortus in Murine Model.

Won K Kim1, Ja Y Moon1, Suk Kim2, Jin Hur1.   

Abstract

Live, attenuated Salmonella Typhimurium vaccine candidate expressing BCSP31, Omp3b, and SOD proteins of Brucella abortus was constructed. Thirty BALB/c mice were divided equally into three groups, Group A, were intraperitoneally (IP) inoculated with 100 μl of approximately 1.2 × 10(6) colony-forming units (CFUs)/ml of the Salmonella containing vector only in 100 μl as a control. And groups B and C mice were orally and IP immunized with approximately 1.2 × 10(9) CFU/ml of the mixture of three delivery strains in 10 μl and IP immunized with approximately 1.2 × 10(6) CFU/ml of the mixture in 100 μl, respectively. The serum IgG, TNF-α and IFN-γ concentrations in groups B (except Omp3b) and C were significantly higher than those in group A. Following challenge with B. abortus strain 544; challenge strain was detected <10(3) CFU from the spleen of all mice of group C. These results suggest that IP immunization with the mixture of the vaccine candidate can induce immune responses, and can effectively protect mice against brucellosis.

Entities:  

Keywords:  Brucella abortus; Salmonella Typhimurium delivery system; brucellosis; vaccine

Year:  2016        PMID: 27148232      PMCID: PMC4837157          DOI: 10.3389/fmicb.2016.00550

Source DB:  PubMed          Journal:  Front Microbiol        ISSN: 1664-302X            Impact factor:   5.640


Introduction

Brucellosis is a zoonotic disease cause infections approximately 500,000 people annually worldwide (Corbel, 1997; Pappas et al., 2005, 2006; Akhvlediani et al., 2010). The disease remains endemic in many regions of the world including Latin America, Middle East, Africa, Asia, and the Mediterranean basin (Pappas et al., 2006). Brucella is predominantly transmitted to humans via direct contact with fluid discharges from infected animals, but in endemic regions people usually get infected through the consumption of unpasteurized dairy products mainly goat’s milk and fresh soft cheese made out of unpasteurized milk (Avila-Calderón et al., 2013). Brucellosis by Brucella species is facultative intracellular bacteria. Brucella infects domestic animals, causing abortion and infertility (Godfroid et al., 2005; Avila-Calderón et al., 2013), however; it can also infect humans producing undulant fever, endocarditis, arthritis and osteomyelitis (Pappas et al., 2005). Both humoral and cell mediated immunities are necessary to change the course of infection of Brucella, but cell mediated response is crucial for clearance of Brucella from host (Schurig et al., 2002). Th1 type of immune response mediated by IFN-γ helps in clearance of Brucella infection (Zhan et al., 1993). Therefore, live and attenuated strains such as Brucella abortus strain 19, B. abortus RB51, Brucella melitensis Rev. 1 and Brucella suis strain 2 have been used to control brucellosis in domestic animals (Cheville et al., 1993; Deqiu et al., 2002; Blaco, 2010; Avila-Calderón et al., 2013; Olsen, 2013). These live and attenuated strains may contain a risk because of its potential possibility to revert virulence bacteria (Goel and Bhatnagar, 2012; Avila-Calderón et al., 2013). In addition, these strains can confuse with the diagnosis of brucellosis in serum (Olsen et al., 2009; Avila-Calderón et al., 2013; Olsen, 2013). Because of these limitations, there is necessary for the development of better vaccines which are safer to use. Brucella can cause host infections via mucosa and then the gastrointestinal tract has been known to be one of the major entrances of infection route of brucellosis (Gorvel et al., 2009). Therefore, mucosal immunity is needed to prevent this enteric infection. Oral vaccination can be successful in inducing levels of protective secretory IgA on the intestinal surface (Melkebeek et al., 2013), however, gastric digestion of vaccines before induction of the immune system is a big barrier in the development of oral vaccines (Melkebeek et al., 2013). Live, attenuated Salmonella strains have been proposed as an adequate vector to deliver orally heterologous proteins and its use can induces protective mucosal immune responses (Branger et al., 2009; Pathangey et al., 2009; Causey et al., 2010). The essential bacterial gene [such as aspartate β-semialdehyde dehydrogenase (asd)]-based balanced-lethal host-vector system has been used to continue plasmids co-expressing inserted antigens in Salmonella Δasd mutants and to escape the use of antimicrobials as marker (Cloeckaert et al., 2002; Hur and Lee, 2011b; Olsen, 2013). Recombinant proteins are a valuable choice for vaccine and can induce antigen specific immune response (Zhao et al., 2009; Goel and Bhatnagar, 2012). An extensively purified protein from Strain 19, the cell surface 31-kilodalton (kDa) protein (or BCSP31), can serve as a protective subunit vaccine in rodents (Tabatabai and Deyoe, 1983; Tabatabai et al., 1989). It has reported that outer membrane proteins (Omps) can be protective antigens of the Brucella species (Verstreate et al., 1982). Omp3b, also known as Omp22, belongs to group 3 of the Brucella Omps (Vizcaino et al., 2004; Garcia-Yoldi et al., 2005), a highly conserved family that includes the most immunogenic Brucella proteins (Cloeckaert et al., 2002). The sodC gene encodes a Cu/Zn superoxide dismutase (SOD; Bricker et al., 1990; Sriranganathan et al., 1991). The SOD could function as virulence factor, since it clears harmful oxy-radicals following phagocytosis by macrophages (Tabatabai and Pugh, 1994). The objective of this study was to evaluate immune responses against B. abortus BCSC31, Omp3b and SOD antigens expressing by live attenuated Salmonella in a murine model. After Salmonella delivery strains with BCSP31, Omp3b, and SOD antigens of B. abortus was constructed, mice were immunized by various inoculation routes with the delivery strains. Immune responses induced via intraperitoneal inoculation with the delivery strains were examined in mice. In addition, we evaluated the efficacy of the delivery strains for protection against experimental brucellosis in mice.

Materials and Methods

Bacterial Strains and Plasmids

The bacterial strains and plasmids used in present study are listed in Table . Wild-type B. abortus biotype 1 isolated from cattle was used to amplify gene encoding BCSP31, Omp3b, and SOD antigens (Table ). B. abortus strain 544 (strain 544) was used as the virulent challenge strain (Lee et al., 2014). The B. abortus biotype 1 isolate was kindly supplied by the National Veterinary Research and Quarantine Service, Korea. The attenuated Salmonella Typhimurium (Δlon ΔcpxR Δasd) mutant strain, JOL912 (Hur and Lee, 2011a) was used as a host for delivery of individual antigens. The pMMP65 plasmid was used as a vector for the expression/secretion of heterologous antigens in the delivery host (Hur and Lee, 2011a). B. abortus isolate and strain 544 were grown in Brucella agar (Becton, Dickinson and Company, Sparks, MD, USA). JOL912 was cultured according to the method in previous studies (Kang et al., 2002; Hur and Lee, 2011a,b). Bacterial strains and plasmids used in this study.

Cloning for Recombinant BCSP31, Omp3b, and SOD Proteins

BCSP31, Omp3b, and SOD proteins were prepared from HJL206, HJL204, and HJL208, respectively (Table ), and were used as coating antigens in enzyme-linked immunosorbent assay (ELISA). In addition, these antigens were used as splenocyte stimulating antigens for cytokines concentration measurement. Briefly, genes for BCSP31, Omp3b, and SOD proteins were amplified by polymerase chain reaction (PCR) using specific primer pairs described in Table . The amplified PCR fragments for each gene were digested with restriction enzymes. Subsequently, the digested fragments were inserted into commercial expression vectors such as pET28a or pET32a. And then these plasmids were transformed into Escherichia coli BL21 in order to create HJL206, HJL204, and HJL208 strains. The recombinant BCSP31, Omp3b, and SOD proteins were prepared using an affinity purification process with nickel-nitrilotriacetic acid-agarose (Qiagen, Valencia, CA, USA) from HJL206, HJL204, and HJL208 respectively. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was used for the confirmation of the integrity of purified antigens. All purified antigens were stored at -70°C until use. Polymerase chain reaction (PCR) primers used in this study and their product sizes.

Preparation of Salmonella Delivery Strains

The delivery strains were prepared as previously described with a slight modification (Hur and Lee, 2011a). The genes for BCSP31, Omp3b, and SOD proteins were prepared by digestion with restriction enzymes from HJL206, HJL204, and HJL208 strains, respectively. And then each gene was inserted in pMMP65 for the construction of vaccine strains. Subsequently, these plasmids were electroporated into JOL912 to create HJL228 for BCSP31, HJL219 for Omp3b and HJL213 for SOD.

Western Blot Analysis

Western blot analysis was carried out to check the secretions of the individual BCSP31, Omp3b, and SOD proteins from HJL228, HJL219, and HJL213, respectively, using the modified method mentioned in previous study (Hur and Lee, 2011a). Briefly, the proteins in supernatant of culture were separated by 12% SDS-PAGE gel and transferred onto polyvinylidene fluoride membranes (Millipore, Billerica, MA, USA). The individual proteins were reacted with anti-His antibodies (Invitrogen, Grand Island, NY, USA) and horseradish peroxidase-conjugated rabbit anti-mouse IgG antibodies (Southern Biotech., Birmingham, AL, USA). Immunoreactive bands were detected by addition of the AmershamTM ECL Prime Western Blotting Detection Reagent (GE Healthcare, Little Chalfont, Buckinghamshire, UK) and the CheBi illumination system (Neo science, Suwon, Gyeonggi, South Korea).

Immunization of Mice and Sample Collection

Thirty 5-weeks-old female BALB/c mice were equally distributed into three groups (n = 10 mice per group). All mice were immunized at 6-weeks-old. Group A mice were intraperitoneally (IP) inoculated with approximately 1.2 × 106 colony-forming units (CFUs)/ml of the Salmonella containing vector only (JHL229) in 100 μl as a control. Group B mice were orally immunized with approximately 1.2 × 109 CFU/ml of the mixture of the three delivery strains in 10 μl. And group C mice were IP immunized with approximately 1.2 × 106 CFU/ml of the mixture of the three delivery strains in 100 μl. Blood samples were collected before immunization [0 week post-immunization (WPI)] and again at the third WPI for the evaluation of serum IgG. All serum samples were stored at -20°C until use. The animal experiments mentioned in this study were performed under ethics approval (CBU 2015-052) from the Chonbuk National University Animal Ethics Committee in accordance with the guidelines of the Korean Council on Animal Care.

Immune Response Measurement by Enzyme-Linked Immunosorbent Assay (ELISA)

A standard ELISA was carried out to evaluate the immune response against BCSP31, Omp3b, and SOD antigens in serum samples of mice according to the modified method of the previous study (Hur and Lee, 2011b). Results of the ELISA are expressed as the mean optical density (OD) ± standard deviation.

Cytokine Quantitation of Splenocytes

At 3 WPI, five mice from each group were sacrificed and spleens were aseptically removed. Splenocytes were prepared according to the method described in previous study (Adone et al., 2012). Splenocytes were distributed in 24 well tissue culture plates with 2 × 106 cells per well (Velikovsky et al., 2003; Cloeckaert et al., 2004). Splenocytes were stimulated in vitro with each BCSP31, Omp3b, and SODC antigen (4 μg/well), Concavalin A (0.5 μg/well) as positive control or media as unstimulated control, and incubated at 37°C, 5% CO2 and 95% humidity (Adone et al., 2012). The supernatants of reaction were collected after 72 h of re-stimulation and used for cytokine measurement (Adone et al., 2012).

Cytokines Measurement by ELISA

The concentration of cytokines such as IFN-γ and TNF-α in the supernatants was evaluated by the mouse cytokine ELISA Ready-SET-GO reagent set according to the instructions of manufacturer (eBioscience, Inc., San Diego, CA, USA).

Challenge Experiments

For challenge experiments, the challenge strain, strain 544 was prepared. Briefly, the strain was cultured in Brucella broth at 37°C for 24 h. and resuspended to approximately 1 × 105 CFU/ml. All mice were IP challenged at 3 WPI with 100 μl of the challenge strain. The spleen weights from all mice were measured and were diluted as 1:100 using Brucella broth. A total of 100 μl of the diluted media was spread on blood agar to count the number of viable strain 544 from the spleens at 2 weeks after the challenge. If no colony detected on the blood agar, means the number of viable challenge strains from the spleen of mice is <103 CFU. The vaccine and challenge strains were confirmed by PCR using B. abortus-specific primer (GAC GAA CGG AAT TTT TCC AAT CCC), RB51/2308 primer (CCC CGG AAG ATA TGC TTC GAT CC) and IS711-specific primer (TGC CGA TCA CTT AAG GGC CTT CAT) in enhanced Brucella AMOS PCR primers (Bricker and Halling, 1994, 1995).

Statistical Analysis

The number of viable strain 544 from the spleens were normalized by log transformation and estimated by one-way analysis of variance, followed by Tukey’s Multiple Comparison Test using GraphPad program (InStat; GraphPad, La Jolla, CA, USA). The antibody and cellular immune responses were compared between the groups by Kruskal–Wallis test and one-way analysis of variance, respectively using SPSS version 16.0 software (SPSS, Chicago, IL, USA).

Results

Secretion of Recombinant BCSP31, Omp3b, and SOD Antigens from Vaccine Candidates

To express the recombinant BCSP31, Omp3b, and SOD proteins from Salmonella, the proteins encoding genes were individually cloned into pMMP65 and were transformed into a ΔlonΔcpxRΔasd S. Typhimurium strain. Western blot analysis was carried out to confirm the secretion of BCSP31, Omp3b and SOD proteins from the culture supernatants of the constructs. The expected sizes, 31 kDa for BCSP31, 22 kDa for Omp3b and 19 kDa for SOD, were observed from the precipitated supernatants of culture the individual constructs (Figure ). Identification of recombinant BCSP31, Omp3b, and SOD proteins secreted from attenuated Lanes: BCSP31, recombinant BCSP31 antigen secreted by JHL228; OMP3b, recombinant Omp3b antigen secreted by JHL219; and SOD, recombinant SOD antigen secreted by HJL213.

Humoral Immune Responses of the Vaccinated Mice

Antibody responses against each antigen in the serum samples are presented in (Figure ). Serum IgG titers against all antigens in groups B (except Omp3b) and C were significantly increased compared to those of control group (P ≤ 0.05). In addition, serum IgG titers against all antigens in group C than group B were significantly higher (P ≤ 0.05). Serum IgG titers against BCSP31, Omp3b, and SOD antigens. Group A mice were intraperitoneally (IP) inoculated with approximately 1.2 × 106 CFU/ml of the Salmonella containing vector only in 100 μl as a control, group B mice were orally immunized with approximately 1.2 × 109 CFU/ml of the mixture of the three delivery strains in 10 μl and group C mice were IP inoculated approximately 1.2 × 106 CFU/ml of the mixture of the three strains in 100 μl. Data are the mean optical density (OD) of all mice in each group, and error bars show the standard deviations (SD). Asterisks indicate a significant difference between the titers of the immunized group and those of the control group (*P < 0.05).

Cytokine Analysis

The TNF-α and IFN-γ concentrations against BCSP31, Omp3b, and SOD antigens in splenocytes re-stimulated with each antigen of mice were measured using ELISA on 3 WPI. The levels of TNF-α and IFN-γ (except Omp3b in group B) were significantly elevated in the groups B and C than group A (P < 0.05; Figure ). Cytokine concentrations in the splenocytes at 3 weeks post-immunization. Groups A–C refer to Figure . Data are the mean of all mice in each group; error bars show SD. Asterisks indicate a significant difference between the values of each group mice (*P < 0.05).

Protection against Challenge

All mice were IP challenged with approximately 1 × 104 CFU of the challenge strain at 3 WPI. The level of protection was evaluated by the number of viable strain 544 from the spleens at 14 days after the challenge. As shown in (Table ), groups B and C mice induced a significantly higher degree of protection than group A. In addition, a significantly higher degree of protection was observed in group C mice than group B mice. Furthermore, among five mice of groups A and B, the challenge strain was isolated from all mice. However, colony was not detected on blood agars spread with broth diluting the spleens of all mice of group C. It means that the number of viable strain 544 from the spleen of group C mice is <103 CFU. Bacterial proliferations in spleen of mice challenged with a wild-type B. abortus strain 544.

Discussion

The small intestine is a major site of nutrient digestion and absorption (Moreto and Perez-Bosque, 2009). In addition, the intestinal epithelium plays a crucial role in the prevention of pathogenic microorganisms entering the interior space of animals (Moreto and Perez-Bosque, 2009). B. abortus can invade hosts through mucosa and is a facultative intracellular bacterium that survives inside phagocytes by escaping the endocytic pathway (Godfroid et al., 2005; Baldwin and Goenka, 2006; Avila-Calderón et al., 2013). The gastrointestinal tract has been known to be one of the major portals of B. abortus infection (Gorvel et al., 2009). Therefore, the host resistance to Brucella infections depends mainly on mucosal immunity and cell-mediated immunity (Baldwin and Parent, 2002; Paranavitana et al., 2005). Live attenuated Brucella vaccines that can stimulate strong mucosal and cell-mediated immune responses are usually very effective against brucellosis (Bricker and Halling, 1994; Murphy et al., 2001; Baldwin and Goenka, 2006). However, live vaccines induce antibodies that confuse the diagnosis of field infection in vaccinated animals (Olsen et al., 2009; Avila-Calderón et al., 2013; Olsen, 2013), which further hinder brucellosis eradication (Velikovsky et al., 2003; Cloeckaert et al., 2004; Izadjoo et al., 2004). In addition, vaccination of pregnant cows with some live vaccine may induce low level abortion or premature birth. Thus it is recommended to be used with caution in pregnant cattle (Olsen et al., 2009; Lin and He, 2012; Avila-Calderón et al., 2013). In previous studies (Chen and Schifferli, 2003; Hur and Lee, 2011a; Hur et al., 2011, 2014) live attenuatted Salmonella, a facultative intracellular bacterium, has been known to induce a strong mucosal immune response as well as cell-mediated immune response. In addition, live attenuated Salmonella, as a vector to transfer heterologous proteins, has many benefits such as delivering the protein to the host, and easy preparation and handy inoculation (Chen and Schifferli, 2003; Hur et al., 2011). Especially, oral immunization with live attenuated Salmonella vaccine expressing the recombinant rBL protein induced significant protective effect, although this protection was lower than that by the inoculation with the pBL DNA vaccine (Zhao et al., 2009). Major Omps of Brucella species have been known to be immunogenic antigens for effective protection against brucellosis (Cloeckaert et al., 2002). In present study, we conducted a new Brucella vaccine candidate, attenuated Salmonella strain expressing Omps of Brucella. We analyzed the immunogenicity and protective efficacy of the vaccine strains against virulent Brucella infection in BALB/c mice immunized via various routes with the candidate. BALB/c mouse has been known to be a proven animal model to study the protection of Brucella vaccine candidates (Jain et al., 2014). In the present study, the attenuated S. Typhimurium Δlon ΔcpxR Δasd strain and the pBP65 plasmid encoding the asd gene (Hur et al., 2011) was used as a delivery system to deliver BCSP31, Omp3b and SOD proteins of B. abortus. Secretion of each antigen from the vaccine candidate was demonstrated by Western blot analysis. This results indicated that the plasmids carrying the genes for BCSP31, Omp3b, and SOD proteins were stably maintained in the vaccine candidates, and that the recombinant BCSP31, Omp3b, and SOD proteins were effectively expressed and secreted. This combination of three S. Typhimurium strains expressing each other protein were determined from preliminary experiments to determine optimal union among various combinations using S. Typhimurium strains expressing each protein, such as BCSP31, Omp3b, Omp10, Omp25, SOD. Two different immunization routes of mice, such as oral (group B) and IP (group C), were used to evaluate the immunogenicity and limitation of colonization of B. abortus strain 544 in spleen. The mice of groups B (except Omp3b) and C induced significant higher amounts of serum IgG titers to BCSP31, Omp3b, and SOD antigens than mice of control group A. These results show that immunization with the vaccine candidate irrespective of inoculation routes can induce systemic immune response. Brucella abortus is a facultative intracellular bacterium. Therefore, cell-mediated immune response is necessary for clearance of the bacteria (Baldwin and Parent, 2002; Paranavitana et al., 2005). Especially, Th1 type immune response is considered as necessary to protect completely brucellosis (Zhan et al., 1996; Murphy et al., 2001; Baldwin and Goenka, 2006). The role of TNF-α to limit colonization of B. abortus in spleen of mice has been known to be critical for activation of macrophages to kill B. abortus in the absence of IFN- γ (Zhan et al., 1996; Murphy et al., 2001). IFN- γ plays a critical role in the clearance of B. abortus by its ability to activate antibacterial functions of infected macrophages (Paranavitana et al., 2005; Baldwin and Goenka, 2006). We studied the cell mediated immune response generated by various immunization routes with the vaccine candidates expressing BSCP31, Omp3b, and SOD antigens of B. abortus. TNF-α and IFN-γ concentrations were evaluated from the supernatants of the re-stimulated splenocytes following restimulation of splenocytes with heat-inactivated B. abortus whole antigens of mice immunized with the vaccine candidates. TNF-α and IFN-γ (except Omp3b in group B) concentrations were significantly higher in groups B and C mice than in group A mice. These results indicate that immunization with the conducts irrespective of inoculation routes may induce strong Th1 type immune responses. Furthermore, significantly high levels of IFN-γ as well as TNF-α in splenocyte culture supernatants relative to group B could be observed in group C. It seems logical to conclude that TNF-α and IFN- γ produced by IP immunization with the candidate can have been associated with the increased protection. The lack of well-established correlation of protection against Brucella is a critical difficulty of a novel vaccine candidate (Zhao et al., 2009). In previous study, oral immunization group with live attenuated Salmonella vaccine expressing the recombinant fusion protein rBL induced significant protection than control group after oral inoculation with B. abortus strain 544 (Zhao et al., 2009). However, the results only showed that the mice immunized with live attenuated Salmonella vaccine expressing the recombinant fusion protein could decreased the number of colonization of Brucella in spleen (Zhao et al., 2009). Similarly, groups B and C mice relative to group A mice significantly limited colonization of B. abortus strain 544 in spleen. These results show that immunization with the candidates irrespective of inoculation routes can protect mice from virulent B. abortus strain 544 infection. Furthermore, in this study, group C mice showed the best protection against virulent B. abortus strain 544 infection. The reason could be that IP immunization with the candidate coffered large amounts of antigens into antigen-presenting cells, which induced the strongest mucosal and cell-mediated immune responses.

Conclusion

The results of this study show that immunization with the Salmonella delivery system based Brucella vaccine induces robust mucosal and cell mediated immune response in mice. Immunization with the vaccine candidate irrespective of inoculation routes confers protection against B. abortus infection. Furthermore, in this study, mice IP immunized with the vaccine candidate showed the best protection against B. abortus strain 544 infections. On theses bases, we believe that IP immunization with the vaccine candidate can effectively protect brucellosis. In addition, these results imply that combination of live, attenuated Salmonella Typhi strains expressing each antigen such as BCSP31, Omp3b, and SOD, may attempt to study as vaccine candidate against human brucellosis, if the attenuated strains should prove safe use in human.

Author Contributions

WK: performed all the tests in this study and wrote this manuscript; JM: assisted the tests and drew the figures; SK: controlled mice; JH: managed this study and wrote this manuscript with WK.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Table 1

Bacterial strains and plasmids used in this study.

Strain/plasmidDescriptionSource
Strains
S. Typhimurium
   JOL912S. Typhimurium ΔlonΔcpxRΔasdHur and Lee, 2011a
   HJL229JOL912 with pMMP65This study
   HJL228JOL912 with pMMP65-BCSP31This study
   HJL219JOL912 with pMMP65-Omp3bThis study
   HJL213JOL912 with pMMP65-SODThis study
B. abortus
   HJL200B. abortus biotype 1 isolate from caw in KoreaLab stock
   HJL254B. abortus strain 544 (ATCC23448)Lee et al., 2014
Plasmids
   pET28aIPTG-inducible expression vector; KmrNovagen
   pET32aIPTG-inducible expression vector; AmprNovagen
   pMMP65Asd+, pBR ori, β-lactamase signal sequence-based periplasmic secretion plasmid, 6x His tagHur and Lee, 2011a
Table 2

Polymerase chain reaction (PCR) primers used in this study and their product sizes.

PrimerSequenceSize (bp)Enzyme siteReference
BCSP31BCSP31-FCCGCGAATTCCAGGCCCCGACATTTTTCCG902EcoRIThis study
BCSP31-RCCGCAAGCTTGGATTATTTCAGCACGCCCGCHindIII
Omp3bOmp3b-FCCGCGAATTCGCCGACATGATGGGAGGGAC563EcoRIThis study
Omp3b-RCCGCAAGCTTACTAGAATTTGTAGTTCAGGCCHindIII
SODSOD-FCCGCGAATTCAAGTCCTTATTTATTGCATCG519EcoRIThis study
SOD-RCCGCAAGCTTTTATTCGATCACGCCGCAGGHindIII
Table 3

Bacterial proliferations in spleen of mice challenged with a wild-type B. abortus strain 544.

GroupLog10CFU/spleen (mean ± SD)Significance (P)
A4.36 ± 0.21
B3.48 ± 0.17<0.05
C<3.0 ± 0.0<0.05
  49 in total

Review 1.  Brucellosis.

Authors:  Georgios Pappas; Nikolaos Akritidis; Mile Bosilkovski; Epameinondas Tsianos
Journal:  N Engl J Med       Date:  2005-06-02       Impact factor: 91.245

Review 2.  Brucellosis vaccines: past, present and future.

Authors:  Gerhardt G Schurig; Nammalwar Sriranganathan; Michael J Corbel
Journal:  Vet Microbiol       Date:  2002-12-20       Impact factor: 3.293

3.  Immunogenicity of Brucella abortus salt-extractable proteins.

Authors:  L B Tabatabai; B L Deyoe; J M Patterson
Journal:  Vet Microbiol       Date:  1989-05       Impact factor: 3.293

4.  Intradermal immunization with outer membrane protein 25 protects Balb/c mice from virulent B. abortus 544.

Authors:  Divya Goel; Rakesh Bhatnagar
Journal:  Mol Immunol       Date:  2012-03-30       Impact factor: 4.407

5.  Development and evaluation as vaccines in mice of Brucella melitensis Rev.1 single and double deletion mutants of the bp26 and omp31 genes coding for antigens of diagnostic significance in ovine brucellosis.

Authors:  Axel Cloeckaert; Isabelle Jacques; Maria Jesus Grilló; Clara M Marín; Maggy Grayon; Jose-Maria Blasco; Jean-Michel Verger
Journal:  Vaccine       Date:  2004-07-29       Impact factor: 3.641

6.  Brucella lumazine synthase elicits a mixed Th1-Th2 immune response and reduces infection in mice challenged with Brucella abortus 544 independently of the adjuvant formulation used.

Authors:  Carlos A Velikovsky; Fernando A Goldbaum; Juliana Cassataro; Silvia Estein; Raúl A Bowden; Laura Bruno; Carlos A Fossati; Guillermo H Giambartolomei
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

7.  Cytokine production in the murine response to brucella infection or immunization with antigenic extracts.

Authors:  Y Zhan; A Kelso; C Cheers
Journal:  Immunology       Date:  1993-11       Impact factor: 7.397

8.  Enhancement of the Brucella AMOS PCR assay for differentiation of Brucella abortus vaccine strains S19 and RB51.

Authors:  B J Bricker; S M Halling
Journal:  J Clin Microbiol       Date:  1995-06       Impact factor: 5.948

9.  Outer membrane proteins of Brucella abortus: isolation and characterization.

Authors:  D R Verstreate; M T Creasy; N T Caveney; C L Baldwin; M W Blab; A J Winter
Journal:  Infect Immun       Date:  1982-03       Impact factor: 3.441

10.  Enhancement of immune responses by an attenuated Salmonella enterica serovar Typhimurium strain secreting an Escherichia coli heat-labile enterotoxin B subunit protein as an adjuvant for a live Salmonella vaccine candidate.

Authors:  Jin Hur; John Hwa Lee
Journal:  Clin Vaccine Immunol       Date:  2010-12-15
View more
  11 in total

1.  Protective efficacy of a Brucella vaccine using a Salmonella-based delivery system expressing Brucella Omp3b, BCSP31, and SOD proteins against brucellosis in Korean black goats.

Authors:  Won-Kyong Kim; Ja-Young Moon; Jeong-Sang Cho; Jin Hur
Journal:  Can J Vet Res       Date:  2019-10       Impact factor: 1.310

2.  Immunogenicity of adenovirus and DNA vaccines co-expressing P39 and lumazine synthase proteins of Brucella abortus in BALB/c mice.

Authors:  Guo-Zhen Lin; Ju-Tian Yang; Suo-Cheng Wei; Shi-En Chen; Sheng-Dong Huo; Zhong-Ren Ma
Journal:  Trop Anim Health Prod       Date:  2018-02-28       Impact factor: 1.559

3.  Protective efficacy by various doses of a new brucellosis vaccine candidate based on Salmonella strains expressing Brucella abortus BSCP31, Omp3b and superoxide dismutase against brucellosis in murine model.

Authors:  Won Kyong Kim; Ja Young Moon; Jeong Sang Cho; Jin Hur
Journal:  Pathog Dis       Date:  2017-09-29       Impact factor: 3.166

4.  Effect of immunization routes and protective efficacy of Brucella antigens delivered via Salmonella vector vaccine.

Authors:  Jonathan Lalsiamthara; Gayeon Won; John Hwa Lee
Journal:  J Vet Sci       Date:  2018-05-31       Impact factor: 1.672

5.  Engineering of a rough auxotrophic mutant Salmonella Typhimurium for effective delivery.

Authors:  Jonathan Lalsiamthara; Je Hyoung Kim; John Hwa Lee
Journal:  Oncotarget       Date:  2018-05-22

6.  Vaccination of goats with a combination Salmonella vector expressing four Brucella antigens (BLS, PrpA, Omp19, and SOD) confers protection against Brucella abortus infection.

Authors:  Mwense Leya; Won Kyong Kim; Jeong Sang Cho; Eun-Chae Yu; Young-Jee Kim; Yoonhwan Yeo; Kwang-Soo Lyoo; Myeon-Sik Yang; Sang-Seop Han; John Hwa Lee; Dongseob Tark; Jin Hur; Bumseok Kim
Journal:  J Vet Sci       Date:  2018-09-30       Impact factor: 1.672

7.  Protective efficacy of a canine brucellosis vaccine candidate based on live attenuated Salmonella expressing recombinant Brucella BCSP31, Omp3b and SOD proteins in Beagles.

Authors:  Won Kyong Kim; Ja Young Moon; Jeong Sang Cho; Byung Yong Park; Jin Hur
Journal:  J Vet Med Sci       Date:  2018-07-31       Impact factor: 1.267

Review 8.  Immune Response to Mucosal Brucella Infection.

Authors:  Rubén López-Santiago; Ana Beatriz Sánchez-Argáez; Liliana Gabriela De Alba-Núñez; Shantal Lizbeth Baltierra-Uribe; Martha Cecilia Moreno-Lafont
Journal:  Front Immunol       Date:  2019-08-20       Impact factor: 7.561

9.  Protective efficacy of attenuated Salmonella Typhimurium strain expressing BLS, Omp19, PrpA, or SOD of Brucella abortus in goats.

Authors:  Mwense Leya; Won Kyong Kim; Enkhsaikhan Ochirkhuyag; Eun Chae Yu; Young Jee Kim; Yoonhwan Yeo; Myeon Sik Yang; Sang Seop Han; John Hwa Lee; Dongseob Tark; Jin Hur; Bumseok Kim
Journal:  J Vet Sci       Date:  2021-03       Impact factor: 1.672

Review 10.  Development and trial of vaccines against Brucella.

Authors:  Jonathan Lalsiamthara; John Hwa Lee
Journal:  J Vet Sci       Date:  2017-08-31       Impact factor: 1.672

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.